QUOTE AND NEWS
SeekingAlpha  Sep 3  Comment 
By Austrolib: The estimates regarding the total cost of diabetes in the US vary wildly, depending on what you count and who is being asked. Forbes put the number at $34B in 2007. The American Diabetes Association put it at $145B that year, and a...
SeekingAlpha  Aug 6  Comment 
ChemoCentryx Inc. (NASDAQ:CCXI) Q2 2014 Earnings Conference Call August 5, 2014 5:00 p.m. ET Executives Susan Kanaya - SVP, Finance, CFO and Secretary Tom Schall - Chairman, President and CEO Analysts Eric Schmidt - Cowen and...
SeekingAlpha  May 9  Comment 
ChemoCentryx Inc. (CCXI) Q1 2014 Earnings Conference Call May 8, 2014 5:00 PM ET Executives Susan Kanaya - SVP, Finance, CFO and Secretary Tom Schall - Chairman, President and CEO Analysts Brian Klein - Stifel Nicolaus ...
Benzinga  Mar 27  Comment 
ChemoCentryx, Inc., (Nasdaq: CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position...
SeekingAlpha  Mar 14  Comment 
ChemoCentryx Inc. (CCXI) Q4 2013 Earnings Conference Call March 13, 2014 05:00 PM ET Executives Susan Kanaya - SVP, Finance and CFO Tom Schall - President and CEO Petrus Bekker - SVP, Clinical and Medical Affairs ...
SeekingAlpha  Feb 11  Comment 
By Herbert Samuel Jennings: Partnership Could Mean High Alpha for ChemoCentryx ChemoCentryx (Nasdaq:CCXI) is a biopharmaceutical smallcap whose pipeline & process [1] are oriented on the development of chemokine pathway drugs. [2] On January...
FierceBiotech  Dec 4  Comment 
A little more than two months after GlaxoSmithKline abandoned its $1.5 billion partnership on ChemoCentryx's lead drug, the Crohn's drug vercirnon, scrapping three late-stage studies after the first Phase III flopped, the biotech says that GSK has...
Benzinga  Dec 4  Comment 
OncoMed Pharmaceuticals (NASDAQ: OMED) surged 8.30% to $30.00 in the pre-market session after Jefferies lifted the price target on the stock from $27 to $46. ChemoCentryx (NASDAQ: CCXI) shares gained 3.59% to $5.20 in the pre-market as the...
StreetInsider.com  Dec 3  Comment 
Omnivision Technologies, Inc. (NASDAQ: OVTI) 13.3% LOWER; reported Q2 EPS of $0.60, $0.17 better than the analyst estimate of $0.43. Revenue for the quarter came in at $397.2 million versus the consensus estimate of $392.3 million. Sees Q3 2014...
StreetInsider.com  Dec 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ChemoCentryx+%28CCXI%29+Repors+Positive+Top-Line+Results+from+CCX168+Phase+II/8944043.html for the full story.




 

ChemoCentryx, Inc. (NASDAQ:CCXI) is a biotechnology company which is developing drugs to help treat Crohn's disease and rheumatoid arthritis. The company's focus has been to target the chemokine system, a system which is known to drive the inflammation process. Using its research platform, Chemocentryx plans to develop future drugs built around targeting the same or similar systems. At the time of its IPO, Chemocentryx did not have any FDA approved drugs.[1]


Business Overview

Chemocentryx was pre-commercially approved drug at the time of its IPO. As a result, its revenues were from collaborative research. In the first nine months of 2011, they reported $5.6M of such revenues and a net loss of $22.8M. The same period in the previous year resulted in $21.7M in revenues and a net loss of $8.2M. [2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on February 8, 2012. The company offered 4.5M shares each for $10. This was below the $14-$16 initial price range. The deal raised a total of $45M. The lead mangers of the deal were JP Morgan, Citi, and Cowen Group (COWN).[3]

Trends & Forces

Reliance on Large Pharmaceutical Companies

Chemocentryx has entered into strategic agreements with GlaxoSmithKline (GSK). These agreements provide for Chemocentryx to conduct the initial clinical trials of candidate drugs and for GSK to pay for and complete the Phase III as well as the marketing and commercialization. Through this agreement, GSK is given the option to exlusively license Chemocentryx's product. While this agreement passes risks and costs associated with drug development to GSK, it also makes Chemocentryx reliant on GSK's abilities to conduct advanced clinical trials and effectively commercialize a product. [4]

  1. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Overview" pg1-3
  2. CCXI S-1/A 2012 PROSPECTUS SUMMARY "SUMMARY FINANCIAL DATA" pg. 9
  3. Renaissance Capital - IPO Home "ChemoCentryx prices downsized IPO at $10, below the range" 8 Feb 2012
  4. CCXI S-1/A 2012 PROSPECTUS SUMMARY "Risk Factors" pg11-13
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki